Orange、CAにおける肺がんの臨床試験
Orangeとその周辺地域（約30マイル以内）の拠点で、肺がんに関する14件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- University of California, Irvine Health, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- UC IRVINE Health, Orange
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
被験者募集中
- Primary Care & Internal Medicine Services, Orange
- UCI Chao Family Comprehensive Cancer Center, Orange
- UCI Health SeniorHealth Center -Pavillion 4, Orange
- 他1件
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
被験者募集中第3相
- Providence St. Joseph Hospital, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
被験者募集中観察研究
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
被験者募集中第2相
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
被験者募集中第2相
- University of California, Irvine Medical Center, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
被験者募集中第2相
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Orange
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
被験者募集中
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- New York City, NY60件の研究
- Los Angeles, CA45件の研究
- Arlington, VA41件の研究
- Washington, DC41件の研究
- Chicago, IL41件の研究
- Baltimore, MD40件の研究
- Nashville, TN40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
Orangeにおける他の研究
- 非小細胞肺癌25件の研究
- 転移性癌20件の研究
- 大腸癌16件の研究
- 卵巣がん16件の研究
- 膵臓がん15件の研究
- 悪性黒色腫14件の研究
- 肝臓がん（肝細胞がん）14件の研究
- 乳がん14件の研究
- 前立腺がん14件の研究
- 胃癌13件の研究
- がん（全種類）13件の研究
- 急性骨髄性白血病13件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。